- Home
- Results news
- Shukra Pharmaceuticals
- Q2 FY27 results
Shukra Pharmaceuticals Q2 FY27 results: net profit ₹12.71 crore
Shukra Pharmaceuticals Ltd reported consolidated revenue of ₹44.20 crore and a net profit of ₹12.71 crore for Q2 FY27, with EBITDA of ₹18.70 crore and an EBITDA margin of 42.3%. The results were approved by the board on 4 November 2026.
Key points
- Consolidated Q2 FY27 revenue was ₹44.20 crore and other income was ₹0.57 crore.
- EBITDA was ₹18.70 crore and the EBITDA margin was 42.3%.
- Profit before tax was ₹17.83 crore, tax was ₹5.12 crore and net profit was ₹12.71 crore.
- Basic EPS was ₹0.29.
- On a standalone basis, revenue was ₹44.20 crore and net profit was ₹16.01 crore.
How did Shukra Pharmaceuticals perform in Q2 FY27?
Shukra Pharmaceuticals reported consolidated revenue of ₹44.20 crore for Q2 FY27, other income of ₹0.57 crore, EBITDA of ₹18.70 crore and an EBITDA margin of 42.3%. Total expenses were ₹26.95 crore, with cost of materials at ₹15.99 crore, employee cost at ₹4.26 crore, finance costs at ₹0.33 crore, depreciation at ₹1.12 crore and other expenses at ₹5.25 crore. There was no exceptional item.
Consolidated profit before tax was ₹17.83 crore for Q2 FY27. Tax was ₹5.12 crore, resulting in a net profit of ₹12.71 crore and basic EPS of ₹0.29. On a standalone basis, revenue was ₹44.20 crore, profit before tax was ₹2.38 crore, net profit was ₹16.01 crore and basic EPS was ₹0.36. The company’s name was changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited with effect from 12 October 2026.
The supplied results do not provide consolidated revenue, EBITDA, margin, profit or EPS for the year-ago quarter or the previous quarter, so a comparison on those measures is not stated. The board approved the unaudited consolidated and standalone results for the quarter and half year ended 30 September 2026 on 4 November 2026, following review by the audit committee.
| ₹ crore | Q2 FY27 |
|---|---|
| Revenue from operations | 44.20 |
| Other income | 0.57 |
| Total expenses | 26.95 |
| EBITDA | 18.70 |
| EBITDA margin | 42.3% |
| Profit before tax | 17.83 |
| Tax | 5.12 |
| Net profit | 12.71 |
| EPS (₹) | 0.29 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹175.26 crore and total equity was ₹117.88 crore, compared with ₹117.44 crore and ₹89.85 crore respectively at 31 March 2026. Borrowings rose to ₹22.50 crore from ₹5.02 crore, while cash fell to ₹0.00 crore from ₹5.98 crore. Inventories were ₹23.42 crore, trade receivables were ₹38.71 crore and trade payables were ₹12.86 crore.
For H1 FY27, operating cash flow was ₹0.43 crore, investing cash flow was ₹15.33 crore, financing cash flow was ₹19.94 crore and capital expenditure was ₹15.56 crore. A year-earlier cash-flow comparison is not available in the supplied results. The filing also stated that convertible warrants issued on a preferential basis were converted into equity shares during the half year, increasing equity share capital.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 175.26 | 117.44 |
| Total equity | 117.88 | 89.85 |
| Borrowings | 22.50 | 5.02 |
| Cash and equivalents | 0 | 5.98 |
| Inventories | 23.42 | 13.90 |
| Trade receivables | 38.71 | 22.95 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 |
|---|---|
| Cash from operations | 0.43 |
| Cash from investing | −15.33 |
| Cash from financing | 19.94 |
| Capital expenditure | 15.56 |
Source: Company's results filing (XBRL).
Which businesses drove the quarter?
The company operated in two reported segments: Shukra Pharmaceutical and Shukra Medtech, with the Medtech segment name effective from 1 October 2025. The Pharmaceutical segment reported revenue of ₹32.27 crore, EBIT of ₹15.06 crore and an EBIT margin of 46.7% in Q2 FY27.
The Medtech segment reported revenue of ₹12.51 crore, EBIT of ₹3.10 crore and an EBIT margin of 24.8% in Q2 FY27. Year-ago revenue and EBIT figures for both segments are not provided in the supplied results, so segment growth against that period is not stated.
| Segment | Revenue | Revenue YoY | EBIT | EBIT margin |
|---|---|---|---|---|
| Pharamaceutical segment | 32.27 | 15.06 | 46.7% | |
| Medtech segment | 12.51 | 3.10 | 24.8% |
Source: Company's results filing (XBRL segment data).
How did other Pharmaceuticals companies do?
Sixty-one Pharmaceuticals companies filed for the quarter as of 4 November 2026. Their median revenue growth was 18.9%. Among the peer set, the number growing slower than Shukra Pharmaceuticals and the number growing faster were not provided in the supplied data. Of the 55 peers for which profit was compared, 39 reported higher profit.
| Shukra Pharmaceuticals revenue growth (YoY) | not comparable |
|---|---|
| Median of 61 other Pharmaceuticals companies | +18.9% |
| Companies whose net profit rose | 39 of 55 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Shukra Pharmaceuticals' revenue in Q2 FY27?
Revenue from operations was ₹44.20 crore (consolidated).
Did Shukra Pharmaceuticals make a profit in Q2 FY27?
Yes. Net profit was ₹12.71 crore.
What was Shukra Pharmaceuticals' EPS in Q2 FY27?
Basic earnings per share were ₹0.29.
When did Shukra Pharmaceuticals announce its Q2 FY27 results?
On 4 November 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended September 2026 (BSE, 22 October 2026) · PDF
- Update on board meeting (BSE, 23 October 2026) · PDF
- Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th September 2026 (BSE, 4 November 2026) · PDF
- Unaudited Financial Results For The Quarter Ended 30Th September 2026 (BSE, 4 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.